Biogenity

Biogenity Biogenity is a data-driven biotechnology company.

🦠 𝗚𝘂𝘁 𝗮𝗻𝗱 𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗲 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘁𝗲𝘀 𝗶𝗻 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 Microbiome-derived metabolites span a wide range of che...
10/11/2026

🦠 𝗚𝘂𝘁 𝗮𝗻𝗱 𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗲 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘁𝗲𝘀 𝗶𝗻 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝘀𝘁𝘂𝗱𝗶𝗲𝘀
Microbiome-derived metabolites span a wide range of chemical classes and biological effects. Interpreting their role often requires integration with host metabolism, lipid regulation, and amino acid turnover.

At Biogenity, microbiome metabolite analyses are designed to integrate with amino acid, bile acid, and lipid panels. Using targeted LC–MS/MS and GC–MS/MS workflows, we deliver reproducible quantitative data across diverse matrices, including f***l samples, biological fluids, and experimental model systems.

This provides a more complete picture of how microbial activity and host pathways interact.

👉 Planning a metabolomics study that includes microbiome-related questions? Let’s discuss panel combinations and study design early on.

🔗 https://biogenity.com/metabolomics/gut-and-microbiome-metabolites

04/11/2026

📄 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗠𝘂𝗹𝘁𝗶𝗺𝗼𝗱𝗮𝗹 𝘀𝗰𝗿𝗲𝗲𝗻 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝘀 𝗻𝗼𝗶𝘀𝗲-𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗽𝗿𝗼𝘁𝗲𝗶𝗻𝘀 (𝟮𝟬𝟮𝟱)
In this Cell Press study, researchers combined single-cell transcriptomics with proteomics to identify proteins that regulate gene-expression noise independently of mean expression levels.

Using a multimodal screening strategy, the team uncovered 32 candidate noise regulators and showed how the nuclear speckle-associated protein SON shapes transcriptional noise, cellular state switching, and fate decisions in mouse embryonic stem cells.

Biogenity contributed to the study by delivering proteomics services as part of the broader experimental framework.

Looking back, it’s a great example of how integrating single-cell RNA data with proteomics can reveal regulatory layers that remain invisible in bulk measurements.

🔗 https://doi.org/10.1016/j.devcel.2025.01.006

𝗜𝘀 𝘁𝗵𝗲𝗿𝗲 𝗮 𝘀𝗽𝗲𝗰𝘁𝗿𝗲 𝗶𝗻 𝘆𝗼𝘂𝗿 𝘀𝗽𝗲𝗰𝘁𝗿𝘂𝗺? 🎃This Halloween, we discuss how the 𝗚𝗵𝗼𝘀𝘁 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗲 may reveal new biology hiding in...
27/10/2026

𝗜𝘀 𝘁𝗵𝗲𝗿𝗲 𝗮 𝘀𝗽𝗲𝗰𝘁𝗿𝗲 𝗶𝗻 𝘆𝗼𝘂𝗿 𝘀𝗽𝗲𝗰𝘁𝗿𝘂𝗺? 🎃
This Halloween, we discuss how the 𝗚𝗵𝗼𝘀𝘁 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗲 may reveal new biology hiding in plain sight.

The “ghost proteome” describes proteins produced from unconventional coding regions - including alternative reading frames within known genes and RNA regions previously considered noncoding. These proteins are absent from the reference databases used in routine proteomics searches, effectively rendering them invisible to standard data analysis pipelines.

𝗪𝗵𝘆 𝗱𝗼𝗲𝘀 𝘁𝗵𝗮𝘁 𝗺𝗮𝘁𝘁𝗲𝗿? A spectrum can only be matched to the database if the corresponding peptide sequence is among the candidates being searched. Our view of the proteome therefore depends on what we tell our software to look for.

And these ghosts may have biological functions. In one study, researchers identified 112 alternative proteins and detected crosslinks connecting some of them to established proteins - providing clues about their interactions and possible functions¹ (reading list in first comment).

Finding them takes more than expanding the database. Larger search spaces also create more opportunities for false matches. Rigorous error control, careful spectrum assessment, and independent validation are essential before assigning a new protein.

The intriguing possibility: some overlooked signals could point to biology we have yet to understand.

Want to hunt for ghosts in your existing raw data files?

👉 𝗪𝗵𝗼 𝘆𝗼𝘂 𝗴𝗼𝗻𝗻𝗮 𝗰𝗮𝗹𝗹..?

Interested in reading more about the ghost proteome? We have included a short reading list in the first comment below.

🎃 As Halloween is fast approaching, we thought it would be fitting to talk about the nightmare of batch effects in omics...
23/10/2026

🎃 As Halloween is fast approaching, we thought it would be fitting to talk about the nightmare of batch effects in omics studies. Most importantly, we outline some straightforward mitigations to avoid the worst of your fears coming true.

Simpson’s paradox neatly captures the dangers of batch effects, but what is it?

21/10/2026

💬 𝗔 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝘄𝗲 𝗼𝗳𝘁𝗲𝗻 𝗴𝗲𝘁 𝗮𝘁 𝗕𝗶𝗼𝗴𝗲𝗻𝗶𝘁𝘆
“𝘊𝘢𝘯 𝘺𝘰𝘶 𝘤𝘰𝘮𝘱𝘢𝘳𝘦 𝘥𝘢𝘵𝘢 𝘢𝘤𝘳𝘰𝘴𝘴 𝘤𝘰𝘩𝘰𝘳𝘵𝘴 𝘰𝘳 𝘢𝘯𝘢𝘭𝘺𝘻𝘦 𝘥𝘢𝘵𝘢 𝘧𝘳𝘰𝘮 𝘢𝘯𝘰𝘵𝘩𝘦𝘳 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘳?”

Sometimes - and we’re transparent about when it makes sense.

Comparing data across cohorts or providers depends on how the data were generated, processed, and documented. When meaningful comparison is possible, we help assess compatibility and ensure conclusions remain reliable.

We also analyse data generated by other providers, as long as it meets standard quality requirements. This allows studies to be extended, combined, or reinterpreted without repeating experiments.

Projects typically start with an exploratory discussion to align objectives and constraints. If we move forward, we establish checkpoints at key stages, from QC review to interpretation, to keep expectations and insights aligned throughout.



👉 𝘞𝘩𝘢𝘵 𝘲𝘶𝘦𝘴𝘵𝘪𝘰𝘯𝘴 𝘴𝘩𝘰𝘶𝘭𝘥 𝘸𝘦 𝘢𝘯𝘴𝘸𝘦𝘳 𝘯𝘦𝘹𝘵 𝘪𝘯 𝘰𝘶𝘳 𝘘&𝘈 𝘦𝘱𝘪𝘴𝘰𝘥𝘦𝘴? 𝘓𝘦𝘵 𝘶𝘴 𝘬𝘯𝘰𝘸 𝘪𝘯 𝘵𝘩𝘦 𝘤𝘰𝘮𝘮𝘦𝘯𝘵𝘴.

𝗕𝗶𝗴 𝗻𝗲𝘄𝘀 𝗳𝗼𝗿 𝗮 𝗣𝗙𝗔𝗦-𝗳𝗿𝗲𝗲 𝗳𝘂𝘁𝘂𝗿𝗲! 🌍Congratulations to PFAS-Free France on being named a finalist for The Earthshot Prize ...
20/10/2026

𝗕𝗶𝗴 𝗻𝗲𝘄𝘀 𝗳𝗼𝗿 𝗮 𝗣𝗙𝗔𝗦-𝗳𝗿𝗲𝗲 𝗳𝘂𝘁𝘂𝗿𝗲! 🌍
Congratulations to PFAS-Free France on being named a finalist for The Earthshot Prize 2026!

"𝘗𝘍𝘈𝘚 '𝘧𝘰𝘳𝘦𝘷𝘦𝘳 𝘤𝘩𝘦𝘮𝘪𝘤𝘢𝘭𝘴' 𝘯𝘰𝘸 𝘤𝘰𝘯𝘵𝘢𝘮𝘪𝘯𝘢𝘵𝘦 𝘦𝘷𝘦𝘳𝘺𝘵𝘩𝘪𝘯𝘨 𝘧𝘳𝘰𝘮 𝘈𝘳𝘤𝘵𝘪𝘤 𝘪𝘤𝘦 𝘵𝘰 𝘩𝘶𝘮𝘢𝘯 𝘣𝘭𝘰𝘰𝘥. 𝘗𝘍𝘈𝘚-𝘍𝘳𝘦𝘦 𝘍𝘳𝘢𝘯𝘤𝘦 𝘭𝘦𝘥 𝘵𝘩𝘦 𝘤𝘰𝘢𝘭𝘪𝘵𝘪𝘰𝘯 𝘵𝘩𝘢𝘵 𝘸𝘰𝘯 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥’𝘴 𝘧𝘪𝘳𝘴𝘵 𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘭𝘢𝘸 𝘣𝘢𝘯𝘯𝘪𝘯𝘨 𝘵𝘩𝘦𝘮, 𝘧𝘰𝘳𝘤𝘪𝘯𝘨 𝘪𝘯𝘥𝘶𝘴𝘵𝘳𝘪𝘦𝘴 𝘵𝘰 𝘳𝘦𝘧𝘰𝘳𝘮𝘶𝘭𝘢𝘵𝘦 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴 𝘢𝘯𝘥 𝘤𝘶𝘵 𝘱𝘰𝘭𝘭𝘶𝘵𝘪𝘰𝘯 𝘢𝘵 𝘵𝘩𝘦 𝘴𝘰𝘶𝘳𝘤𝘦.”
- 𝙏𝙝𝙚 𝙀𝙖𝙧𝙩𝙝𝙨𝙝𝙤𝙩 𝙋𝙧𝙞𝙯𝙚

Regulation only works when contamination can be measured. At Biogenity, we proudly provide the precision analytical services needed to identify and quantify PFAS in anything from soil to human and animal tissues. The science underpinning a cleaner, healthier future.

🧬 𝗢𝗹𝗶𝗻𝗸 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗶𝗻 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 Olink proteomics is particularly well-suited for projects that require repr...
15/10/2026

🧬 𝗢𝗹𝗶𝗻𝗸 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗶𝗻 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵
Olink proteomics is particularly well-suited for projects that require reproducible, scalable protein data with translational potential. This includes studies that bridge discovery and validation or support clinical hypothesis generation.

At Biogenity, we help researchers assess when Olink proteomics is the appropriate tool and how to design studies that fully leverage its strengths.

𝗠𝗼𝘃𝗶𝗻𝗴 𝗳𝗿𝗼𝗺 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘁𝗼𝘄𝗮𝗿𝗱 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻? Let’s discuss whether Olink proteomics fits your translational strategy.

🔗 https://biogenity.com/olink-proteomics

💊 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗲 𝗱𝘆𝗻𝗮𝗺𝗶𝗰𝘀 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 𝗶𝗻 𝗱𝗿𝘂𝗴 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 In drug development, changes in protein abundance alone rarely e...
13/10/2026

💊 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗲 𝗱𝘆𝗻𝗮𝗺𝗶𝗰𝘀 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 𝗶𝗻 𝗱𝗿𝘂𝗴 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝘀𝘁𝘂𝗱𝗶𝗲𝘀
In drug development, changes in protein abundance alone rarely explain how a compound acts. Distinguishing between proteins that are already present and those that are newly produced provides a more informative view of drug mechanism and specificity.

Proteome dynamics profiling separates mature and nascent proteins, enabling assessment of which proteins are stabilized or degraded after drug treatment and which exhibit altered production rates. This added resolution supports early evaluation of on-target and off-target effects that may be missed by standard global proteomics.

At Biogenity, this approach is used when understanding how a drug perturbs the proteome is as important as identifying which proteins change.

💬 Investigating drug mechanism or specificity at the protein level? Let’s discuss whether proteome dynamics profiling fits your study.

🔗 https://biogenity.com/proteomics-drug-development

09/10/2026

📄 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗔𝗰𝘂𝘁𝗲 𝗽𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗼𝗳 𝗕𝗮𝗰𝗶𝗹𝗹𝘂𝘀 𝘀𝘂𝗯𝘁𝗶𝗹𝗶𝘀 𝗗𝗘𝟭𝟭𝟭 (𝟮𝟬𝟮𝟮)
Looking back at this randomized, double-blinded, placebo-controlled human study published in Beneficial Microbes - scientific journal, the researchers set out to explore what happens in the human small intestine just hours after probiotic ingestion - a biological window that is rarely accessible.

Using ileostomy samples collected four hours after oral intake of Bacillus subtilis DE111, the study combined metabolomics, proteomics, and metagenomics to capture early molecular responses. The results revealed rapid changes in metabolic profiles, immune-related protein expression, and lipid-associated pathways, while microbiome composition remained largely stable aside from the presence of the probiotic itself.

Biogenity provided proteomics data acquisition, processing, and analysis, supporting protein-level insights into immune regulation and lipid metabolism observed shortly after ingestion. 

Looking back, studies like this highlight how integrated omics approaches can reveal immediate physiological effects that would otherwise remain hidden.

🔗 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗮𝗿𝘁𝗶𝗰𝗹𝗲: https://doi.org/10.3920/BM2022.0081

30/09/2026

📆 𝗕𝗶𝗼𝗴𝗲𝗻𝗶𝘁𝘆 𝗮𝘁 𝘁𝗵𝗲 𝟳𝘁𝗵 𝗗𝗦𝗘𝗩 𝗔𝗻𝗻𝘂𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲
This Thursday, October 1st, Paul Manna from Biogenity will be at the 7th Annual Symposium of the Danish Society for Extracellular Vesicles (DSEV) at the University of Copenhagen.

From EV characterisation to biomarker discovery, the programme touches many of the areas we work in every day. As a CRO for proteomics, transcriptomics and metabolomics, we support researchers from study design to data delivery.

If you are working with extracellular vesicles and want to talk about your next study, find Paul during the breaks or message him on LinkedIn to arrange a time. We are looking forward to attending this year's EV Symposium.

Adresse

Niels Jerns Vej 10
Aalborg
9220

Åbningstider

Mandag 09:00 - 16:00
Tirsdag 09:00 - 16:00
Onsdag 09:00 - 16:00
Torsdag 09:00 - 16:00
Fredag 09:00 - 16:00

Underretninger

Bliv den første, der får besked: Vi sender dig en e-mail, når Biogenity offentliggør nyheder og tilbud. Din e-mailadresse bliver ikke brugt til andre formål, og du kan til enhver tid afmelde dig.

Genveje

Del

Kategori

Computer Og Elektronik Tjenester i nærheden